Vimarsana
Biggest News Aggregation in the World

Page 22 - Confidence Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Confidence Interval Today - Breaking & Trending Today

Long-Term Data for Kite's Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma - Vimarsana News

Long-Term Data for Kite's Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

Carrier status of an actionable gene is associated with reduced life span in large Icelandic study - Vimarsana News

Carrier status of an actionable gene is associated with reduced life span in large Icelandic study

1. In this cross-sectional study, having carrier status of actionable genes identified by the American College of Medical Genetics and Genomics (ACMG) was associated with reduced life span compared to non-carrier status. 2. Having carrier status for an actionable cancer gene was associated with a shorter life span by an average of three years compared

Five modifiable risk factors contribute to cardiovascular disease and mortality - Vimarsana News

Five modifiable risk factors contribute to cardiovascular disease and mortality

1. In this retrospective cohort study, five risk factors (body mass index, systolic blood pressure, non–high-density lipoprotein cholesterol, current smoking, and diabetes) contributed to increased incidence of cardiovascular disease. 2. These factors were also noted to increase the risk of death from any cause. Evidence Rating Level: 2 (Good) Study Rundown: Modifiable risk factors such

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023 - Vimarsana News

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023

New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of response with Reblozyl® compared to epoetin alfa ...

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of - Vimarsana News

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of

New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of response with Reblozyl® (luspatercept-aamt) compared to epoetin alfaPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #ASH--Bristol Myers Squibb (NYSE: BMY) announced updated results from the primary...